Neurocrine Biosciences to present at 2026 Jefferies Global Healthcare Conference in London on Nov 17.

Neurocrine Biosciences announced its executives will participate in the 2026 Jefferies Global Healthcare Conference in London on November 17, 2026. The presentation will be webcast live and available for replay on the company's website. Neurocrine is a biopharmaceutical company focused on developing treatments for neurological, psychiatric, endocrine, and immunological disorders, with several FDA-approved drugs and a strong pipeline. This event offers investors insight into the company's progress and future plans.

Neurocrine Biosciences shares trade at USD 169.22 on Pluang as of Nov 11, 2026 04:02 WIB, up 0.21% for the day. The stock's market cap stands at $17.09 billion with a 52-week range between $123.10 and $185.50. Despite recent news, Pluang order activity shows 100% sell interest, with a typical hold time of 27 days.